Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05929677 · ClinicalTrials.gov registry record · Early Phase 1
Impulsivity Domains and Subjective Response
A Early Phase 1 study of Alcohol Use Disorder, sponsored by Jessica Weafer.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 250
- Enrollment target
- 2
- Study locations
NCT05929677: Recruiting Early Phase 1 study of Alcohol Use Disorder, sponsored by Jessica Weafer.
NCT05929677 is a Early Phase 1 study of Alcohol Use Disorder that is actively recruiting participants, run by Jessica Weafer. The registered enrollment target is 250 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (24% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05929677, a Early Phase 1 study of Alcohol Use Disorder, is actively recruiting participants, sponsored by Jessica Weafer.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 250 participants
- Enrollment target
- 2
- Study locations
Study Summary
Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol. The results will identify badly needed, novel targets for prevention and treatment efforts to simultaneously reduce impulsivity and subjective responses in at-risk young adults.
Primary Outcome
Participants provide subjective ratings of stimulation and sedation using the Brief Biphasic Alcohol Effects Scale (scores from 0 to 10 where a higher number means more stimulation/sedation).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Alcohol
Study Locations (2)
Massachusetts
- Northeastern University - Boston
Ohio
- Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2027-09-01 |
| Phase | Early Phase 1 |
What NCT05929677 shows while recruiting
NCT05929677 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05929677 reports a single indexed study location in Massachusetts, Ohio.
Frequently Asked Questions
What is clinical trial NCT05929677 about?
NCT05929677 is a clinical study titled "Impulsivity Domains and Subjective Response". Findings from this project will determine the relationship between two vulnerability factors for Alcohol Use Disorder (AUD) in young adults: impulsivity and subjective response to alcohol. The results will identify badly needed, novel targets for prevention and treatment efforts to simultaneously re...
What is the current status of trial NCT05929677?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 250 participants. The study started on 2024-04-01. Estimated completion is 2027-09-01.
What conditions does trial NCT05929677 study?
This clinical trial studies the following conditions: Alcohol Use Disorder.
What interventions are being tested in trial NCT05929677?
The interventions under investigation include: Placebo (DRUG), Alcohol (DRUG).
Who is sponsoring clinical trial NCT05929677?
This trial is sponsored by Jessica Weafer, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05929677 being conducted?
This trial has 2 study locations across Massachusetts, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05929677's enrollment target sits among peer trials
250 33rd of 184 higher than 149 of 184 other Alcohol Use Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alcohol Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder
RECRUITING · Early Phase 1
-
Suvorexant and Alcohol
RECRUITING · Early Phase 1
-
Anxiety During Abstinence in AUD
RECRUITING · Early Phase 1
-
Diclofenac as a KMO Inhibitor
ACTIVE NOT RECRUITING · Early Phase 1
-
Behavioral Alcohol Responses (BAR) Study
ACTIVE NOT RECRUITING · Early Phase 1
-
Imaging Inflammation With Alcohol Use Disorder: an [18F]NOS Study
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI